Edgewise Therapeutics to Present at Upcoming Investor Conferences
May 02 2023 - 8:00AM
Business Wire
Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage
biopharmaceutical company focused on developing orally
bioavailable, targeted, small molecule therapies for the treatment
of devastating muscle disorders, announced today that management
will participate in fireside chats at two upcoming investor
conferences:
BofA Securities 2022 Healthcare Conference
Presentation: Tuesday, May 9, 2023 at 8:55 am PDT (11:55 am
ET)
RBC Capital Markets Global Healthcare Conference
Fireside chat: Tuesday, May 16, 2023 at 11:30 am ET
The presentations will be webcast live under the Edgewise events
page. It is recommended that users connect to the webcasts several
minutes prior to the start to ensure a timely connection. Replays
of the webcasts will be available on Edgewise’s website for a
limited time following the conferences.
About Edgewise Therapeutics
Edgewise Therapeutics is a clinical-stage biopharmaceutical
company focused on the discovery, development, and
commercialization of innovative treatments for severe, rare
neuromuscular and cardiac disorders for which there is significant
unmet medical need. Guided by its holistic drug discovery approach
to targeting the muscle as an organ, Edgewise has combined its
foundational expertise in muscle biology and small molecule
engineering to build its proprietary, muscle-focused drug discovery
platform. Edgewise’s platform utilizes custom-built high throughput
and translatable systems that measure integrated muscle function in
whole organ extracts to identify small molecule precision medicines
regulating key proteins in muscle tissue. The Company’s lead
candidate, EDG-5506, an investigational orally administered small
molecule myosin modulator designed to protect injury-susceptible
fast skeletal muscle fibers in dystrophinopathies, is advancing in
multiple clinical trials in individuals with Duchenne, Becker and
Limb Girdle 2I muscular dystrophies, and McArdle’s disease. The
Company is also advancing EDG-7500, a novel sarcomere modulator for
hypertrophic cardiomyopathy, into IND-enabling preclinical
development. To learn more, go to: www.edgewisetx.com or follow us
on LinkedIn, Twitter and Facebook.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230502005106/en/
Investors & Media Michael Carruthers Chief Financial
Officer ir@edgewisetx.com
Edgewise Therapeutics (NASDAQ:EWTX)
Historical Stock Chart
From Apr 2024 to May 2024
Edgewise Therapeutics (NASDAQ:EWTX)
Historical Stock Chart
From May 2023 to May 2024